For additional information, visit: www.neutrophase.com .

Cautionary Information Regarding Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the expected timing of enrollment and commencement of clinical trials, expected timing of receipt and announcement of results of clinical studies, and efficacy of NeutroPhase and Aganocides. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

1 Hui YH (ed.), 2006. Handbook of Food Science, Technology, And Engineering, Vol. 4. p. 193-24. CRC Press, Boca Raton, FL.
CONTACT: NovaBay Business Development and Licensing:         Roy J. Wu         Sr. VP Business Development         (510) 899-8815         BusDev@novabaypharma.com                  Investors:         NovaBay Pharmaceuticals, Inc.                  Thomas J. Paulson         Chief Financial Officer         510-899-8809         tjpaulson@NovaBaypharma.com                  Investors and Media:         The Ruth Group                  Nicole Greenbaum (Investors)         (646) 536-7009         ngreenbaum@theruthgroup.com                  Victoria Aguiar (Media)         (646) 536-7013         vaguiar@theruthgroup.com

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Breakouts

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders